August 25, 2022

August 25, 2022

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor Among Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Real-World Study of a Large U.S. Database

Some see CLL/SLL as a solved problem. But unfortunately, we know better. This abstract from the European Hematology Association (EHA) Annual Congress in 2022 reinforced one of our greatest unsolved problems: what happens following treatment with a covalent BTK and BCL2 inhibitor.

August 25, 2022

We Need Your Help: The FDA Will Be Reviewing Whether Duvelisib Should Be Withdrawn or Continue to be Approved for Relapsed/Refractory CLL

CLL Society would like to make a special request to all of those who have CLL/SLL in our community to please consider submitting a personal comment to the FDA regarding the possibility of duvelisib being removed as an available treatment option.

August 25, 2022

ASCO 2022: Influence of Racial and Ethnic Identity on Overall Survival in Patients With Chronic Lymphocytic Leukemia

The Bottom Line: Black CLL patients die sooner than their white counterparts, even when controlling for other risk factors. In addition, the gap in overall survival has not improved between 2004 to 2018.

August 25, 2022

ASCO 2022: Incidence, Predictors, and Outcomes of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia

CLL patients are at higher risk for several types of cardiac events and have higher rates of in-hospital mortality, regardless of why they were admitted. In addition, this trial was seriously flawed as it did not address what CLL treatments were used. We know certain therapies such as BTKi,

August 25, 2022

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL. This is a powerful combination with impressively durable responses in both TN and R/R patients.

August 25, 2022

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, Dr. Bill Wierda of MDACC presented the follow-up three-year data of the fixed duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (treatment) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

August 25, 2022

ASCO 2022: Acalabrutinib Versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): ASCEND Results at 4 Years of Follow-Up

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial. This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

August 25, 2022

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor Among Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Real-World Study of a Large U.S. Database

We Need Your Help: The FDA Will Be Reviewing Whether Duvelisib Should Be Withdrawn or Continue to be Approved for Relapsed/Refractory CLL

ASCO 2022: Influence of Racial and Ethnic Identity on Overall Survival in Patients With Chronic Lymphocytic Leukemia

ASCO 2022: Incidence, Predictors, and Outcomes of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

ASCO 2022: Acalabrutinib Versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): ASCEND Results at 4 Years of Follow-Up

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT